Feb 11, 2025 7:00am EST Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study
Feb 05, 2025 7:00am EST Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment
Jan 06, 2025 7:00am EST Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent
Jul 16, 2024 8:00am EDT Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
